Business
Approval of CARDIO inCode-score in New York state
GENinCode Plc has received approval from the New York State Department of Health for its CARDIO inCode-Score® Polygenic Risk Score test, enabling its inclusion in the 2025 Clinical Laboratory Fee Schedule with an average reimbursement of approximately $500.00 per test, and allowing sample collection from New York physicians for testing at their California facility. This approval signifies rigorous validation and supports the company's ongoing FDA De Novo assessment, with further data submission expected in Q1 2026 for broader US market access. Disclaimer*
About this update from Genincode Plc
[{"type":"text","content":"\n\n3 December 2025\nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nNew York State clinical test approval of CARDIO inCode-score®\n \nGENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of coronary heart disease (\"CHD\" or \"Heart Disease\") and risk assessment of ovarian cancer, announces today the test approval by the New York State Department of Health, Clinical laboratory Evaluation Program, of CARDIO inCode-Score® Polygenic Risk Score (\"PRS\") for the prediction and prevention of coronary heart disease.\n \nThe approval of CARDIO inCode-Score® test by New York State now enables full state coverage under US Centers for Medicare and Medicaid Services (CMS) with the test included in the 2025 Clinical Laboratory Fee Schedule at an average reimbursement of ~$500.00 per test. \n \nNew York State clinical test approval requires rigorous analytical and clinical test validation, extensive quality documentation and the completion of a comprehensive application and laboratory audits. Test approval of CARDIO inCode-Score® allows GENinCode to collect patient samples from New York State physicians, clinics, and health institutions for testing at its Irvine, California lab facility which has also received a New York State clinical test permit.\n \nCARDIO inCode-Score® is a clinically validated, commercially available polygenic risk score based on DNA extracted from a simple saliva or blood sample. The extracted DNA is scored to identify an individual's inherited genetic risk of heart disease thereby enabling prevention through lifestyle change and/or therapeutic treatment. The test has been designed and optimized for population-based risk prediction and primary prevention of heart disease.\n \nGENinCode continues to progress discussions with the FDA and expects to submit additional data requested to complete its De Novo assessment in Q1. 2026. Approval by the FDA is required to sell the test in a medical device/kit format that can be used across a broad range of US laboratories.\n \nMatthew Walls, GENinCode Chief Executive Officer said: \"Following careful evaluation by the New York State Department of Health, we are delighted to receive CARDIO inCode-Score® test approval to commercially promote CARDIO inCode-Score® for genetic...